Jianyong Xu1,2, Jieting Chen3, Wenlei Li4, Wei Lian2, Jieyong Huang2, Baoyu Lai2, Lingyun Li2, Zhong Huang1,2. 1. Guangdong Provincial Key Laboratory of Regional Immunity and Disease and xujianyong@szu.edu.cn zhuang809@126.com. 2. Department of Immunology, Health Science Center, Shenzhen University, Shenzhen, P.R. China. 3. Department of Obstetrics, People's Hospital of Baoan, Shenzhen, P.R. China; and. 4. Department of Obstetrics, Women and Children Health Institute of Futian, Shenzhen, P.R. China.
Abstract
BACKGROUND: Although mesenchymal stem cells (MSCs) might offer a promising strategy for treating SLE, their immunoregulatory plasticity makes their therapeutic effects unpredictable. Whether overexpressing IL-37, an IL-1 family member with immunosuppressive activity, might enhance the therapeutic effects of these cells for SLE is unknown. METHODS: We genetically modified MSCs to overexpress IL-37 and assessed their effects on immune suppression in vitro. We also evaluated the effects of such cells versus effects of various controls after transplanting them into MRL/lpr mice (model of SLE). RESULTS: Stem cell characteristics did not appear altered in MSCs overexpressing IL-37. These cells had enhanced immunosuppression in vitro in terms of inhibiting splenocyte proliferation, reducing proinflammatory factors (IL-1β, TNF-α, IL-17, and IL-6), and suppressing autoantibodies (anti-dsDNA and anti-ANA). Compared with animals receiving control MSCs or IL-37 treatment alone, MRL/lpr mice transplanted with IL-37-overexpressing cells displayed improved survival and reduced signs of SLE (indicated by urine protein levels, spleen weight, and renal pathologic scores); they also had significantly lower expression of proinflammatory factors, lower total antibody levels in serum and urine, lower autoantibody production, and showed reduced T cell numbers in the serum and kidney. Expression of IL-37 by MSCs can maintain higher serum levels of IL-37, and MSCs had prolonged survival after transplantation, perhaps through IL-37 suppressing the inflammatory microenvironment. CONCLUSIONS: Mutually reinforcing interaction between MSCs and IL-37 appears to underlie their additive therapeutic effects. Genetic modification to overexpress IL-37 might offer a way to enhance the stability and effectiveness of MSCs in treating SLE.
BACKGROUND: Although mesenchymal stem cells (MSCs) might offer a promising strategy for treating SLE, their immunoregulatory plasticity makes their therapeutic effects unpredictable. Whether overexpressing IL-37, an IL-1 family member with immunosuppressive activity, might enhance the therapeutic effects of these cells for SLE is unknown. METHODS: We genetically modified MSCs to overexpress IL-37 and assessed their effects on immune suppression in vitro. We also evaluated the effects of such cells versus effects of various controls after transplanting them into MRL/lpr mice (model of SLE). RESULTS: Stem cell characteristics did not appear altered in MSCs overexpressing IL-37. These cells had enhanced immunosuppression in vitro in terms of inhibiting splenocyte proliferation, reducing proinflammatory factors (IL-1β, TNF-α, IL-17, and IL-6), and suppressing autoantibodies (anti-dsDNA and anti-ANA). Compared with animals receiving control MSCs or IL-37 treatment alone, MRL/lpr mice transplanted with IL-37-overexpressing cells displayed improved survival and reduced signs of SLE (indicated by urine protein levels, spleen weight, and renal pathologic scores); they also had significantly lower expression of proinflammatory factors, lower total antibody levels in serum and urine, lower autoantibody production, and showed reduced T cell numbers in the serum and kidney. Expression of IL-37 by MSCs can maintain higher serum levels of IL-37, and MSCs had prolonged survival after transplantation, perhaps through IL-37 suppressing the inflammatory microenvironment. CONCLUSIONS: Mutually reinforcing interaction between MSCs and IL-37 appears to underlie their additive therapeutic effects. Genetic modification to overexpress IL-37 might offer a way to enhance the stability and effectiveness of MSCs in treating SLE.
Authors: Tessa S van Kempen; Mark H Wenink; Emmerik F A Leijten; Timothy R D J Radstake; Marianne Boes Journal: Nat Rev Rheumatol Date: 2015-05-12 Impact factor: 20.543
Authors: Onkar Kulkarni; Rahul D Pawar; Werner Purschke; Dirk Eulberg; Norma Selve; Klaus Buchner; Volha Ninichuk; Stephan Segerer; Volker Vielhauer; Sven Klussmann; Hans-Joachim Anders Journal: J Am Soc Nephrol Date: 2007-07-11 Impact factor: 10.121
Authors: Mai Abdelgawad; Nourhan Saied Bakry; Ahmed A Farghali; Ahmed Abdel-Latif; Ahmed Lotfy Journal: Stem Cell Res Ther Date: 2021-08-21 Impact factor: 6.832